Synendos Therapeutics, one of our Portfolio companies, announced today raising USD 21 Million!
We are very proud to announce that Synendos Therapeutics has raised a USD 21M series A co-led by Kurma Partners and Sunstone Life Science Ventures. Synendos, a spin-off from the University of Bern, develops novel therapeutics for unmet medical needs in anxiety, mood and stress-related disorders, based on completely novel insights into the endocannabinoid system.
Raising institutional financing is always challenging but doing so in the middle of a global pandemic is truly an extraordinary achievement. So, big congratulations to Andrea Chicca, Jürg Gertsch and Simon Russell on this important step towards developing game changing treatments for patients suffering from neuropsychiatric disorders.
See the full press release here.
And, read their success story as a BaseLaunch Portfolio company here.
